Lemaitre Vascular Intrinsic Value Calculation – LeMaitre Vascular receives “outperform” rating from Barrington Research in latest investor note

🌥️Trending News

LEMAITRE ($NASDAQ:LMAT): LeMaitre Vascular is a leading global provider of medical devices for the treatment of peripheral vascular disease. The company offers a comprehensive portfolio of products, including grafts, stents, and catheters, to support the diagnosis and treatment of conditions such as blocked or narrowed arteries. With a strong commitment to innovation and excellence, LeMaitre Vascular has become a trusted name in the medical community. Recently, the company received praise from investment firm Barrington Research in their latest note to investors. The note reaffirmed LeMaitre Vascular’s “outperform” rating, highlighting the company’s strong financial performance and potential for future growth. One key factor contributing to the positive outlook for LeMaitre Vascular is its impressive financial results. Moreover, LeMaitre Vascular’s diverse product portfolio has positioned it for success in the rapidly growing peripheral vascular market. The company’s offerings cater to a wide range of procedures and patient needs, making it a go-to choice for healthcare professionals.

This, combined with its strong customer relationships and distribution network, bodes well for its future growth potential. In addition to its financial performance and market presence, LeMaitre Vascular has also made significant strides in innovation. The company recently launched the MANTA™ vascular closure device, a tool designed to simplify and improve the closure of large-bore arterial access sites. This product has received positive reviews from healthcare professionals and is expected to drive further revenue growth for the company. In light of these factors, it is no surprise that Barrington Research has reaffirmed its “outperform” rating for LeMaitre Vascular’s stock. With a solid foundation of financial stability, a diverse product portfolio, and a commitment to innovation, the company is well-positioned for continued success and growth in the years to come. Investors can confidently look to LeMaitre Vascular as a strong choice in the medical device industry.

Share Price

This news comes as a boost for the company, as it indicates confidence in their financial performance and growth potential. On Friday, the stock for LeMaitre Vascular opened at $90.18 and closed at $89.96, showing a slight decrease of 0.24% from the previous closing price. Despite this dip, the stock has been performing well overall with a strong upward trend over the past year. This can be attributed to the company’s steady revenue growth and expansion into new markets. Barrington Research’s “outperform” rating is based on their analysis of LeMaitre Vascular’s financials and future prospects. They have recognized the company’s solid track record of profitability and their innovative product portfolio. LeMaitre Vascular offers a range of devices for the treatment of various vascular conditions, including stents, grafts, and catheters.

The company has also been actively expanding its global presence, with a significant portion of their revenue coming from international markets. This diversification strategy has helped to mitigate any potential risks associated with fluctuations in the US market. Moreover, LeMaitre Vascular has a strong focus on research and development, constantly striving to improve their existing products and develop new ones. This commitment to innovation has enabled them to capture a significant share of the vascular device market and stay ahead of competitors. With this positive rating from Barrington Research, investors can be assured of LeMaitre Vascular’s solid financials and growth potential. As the company continues to expand its product offerings and global reach, it is poised for continued success in the future. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Lemaitre Vascular. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Lemaitre Vascular. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Lemaitre Vascular. More…

Key Ratios Snapshot

Some of the financial key ratios for Lemaitre Vascular are shown below. More…

Analysis – Lemaitre Vascular Intrinsic Value Calculation

After conducting a thorough analysis, I have determined that LEMAITRE VASCULAR‘s well-being is in good standing. This medical device company specializes in designing, marketing, and selling medical devices for the treatment of peripheral vascular disease. Their products have been well-received in the market, leading to strong financial performance. In terms of intrinsic value, our proprietary Valuation Line indicates that LEMAITRE VASCULAR’s share is currently worth around $59.5. This calculation takes into account various factors such as the company’s financial performance, industry trends, and future growth potential. Therefore, based on this valuation, the stock is currently overvalued by 51.2%. At the time of writing, LEMAITRE VASCULAR’s stock is trading at $89.96 per share, which is significantly higher than its intrinsic value. This suggests that the stock is currently overvalued and may not be a good investment opportunity at its current price. Investors should carefully consider this information before making a decision to buy or sell LEMAITRE VASCULAR stock. In conclusion, while LEMAITRE VASCULAR is a solid company with good financial health, its stock appears to be overvalued at the moment. As always, it is important for investors to conduct their own research and make informed decisions based on their financial goals and risk tolerance. More…

Peers

It focuses on the development, manufacture and marketing of minimally invasive products for the treatment of peripheral vascular diseases. The company operates through two segments, Direct and OEM. The Direct segment offers proprietary products to hospitals and other medical institutions through direct sales force. The OEM segment provides stents and other products to Original Equipment Manufacturers (OEMs) for sale under their own brands. LeMaitre’s competitors include Atrion Corp, Implanet SA, Vycor Medical Inc.

– Atrion Corp ($NASDAQ:ATRI)

Atrion Corporation is a medical device company that develops, manufactures and markets products primarily for use in cardiac and ophthalmic surgery. The company’s products include Cardiax, a cannula used in cardiac surgery; Ophthalmic products, including the HydroVue and Glaucoma Shunt systems to treat glaucoma; and PerQCat, a catheter used in urology procedures.

– Implanet SA ($OTCPK:IMPZY)

Implanet SA is a French company specializing in the design and manufacture of medical implants for the treatment of orthopedic pathologies. The company’s products are used in the treatment of various conditions, including osteoarthritis, degenerative disc disease, scoliosis, and deformities of the hip, knee, and shoulder. As of 2022, Implanet SA had a market capitalization of 3.88 million euros and a return on equity of -114.56%. The company’s products are sold in over 50 countries worldwide and its customers include some of the world’s leading orthopedic surgeons and hospitals.

– Vycor Medical Inc ($OTCPK:VYCO)

Vycor Medical Inc is a medical device company that specializes in the development and commercialization of minimally invasive products for neurosurgery. The company’s products are designed to provide surgeons with improved access and visualization during surgery, while minimizing tissue damage and surgical time. Vycor Medical’s products are sold in over 30 countries worldwide.

As of 2022, Vycor Medical Inc had a market capitalization of 3.17 million and a return on equity of 6.36%. The company’s products are used in a variety of neurosurgical procedures, including brain surgery, spinal surgery, and skull-base surgery.

Summary

Barrington Research has recently reaffirmed their “outperform” rating for LeMaitre Vascular‘s stock. This indicates that the company’s stock is expected to outperform the overall market. Investors may see this as a positive sign for the company, as it could suggest strong financial performance in the future.

However, it is important to conduct further analysis and research before making any investment decisions. Factors such as the company’s financial health, competitive landscape, and industry trends should also be taken into consideration. Overall, this reaffirmation of the “outperform” rating may be seen as a vote of confidence in LeMaitre Vascular and could potentially attract more investors to the company’s stock.